Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying dasatinib to see how well it works in treating patients with
previously treated metastatic colorectal cancer. Dasatinib may stop the growth of tumor cells
by blocking some of the enzymes needed for their growth.